Acurx Pharmaceuticals, Inc. (ACXP) stock
ACXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.96−0.03 (-2.54%)
Close on Nov 13, 2026Market cap $5.06MP/E –Yield –
Acurx Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Acurx Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $2.81M, up 18.2% year over year. For fiscal 2025 it was $1.83M, down 66.1% from the year before. The highest annual figure on record is $6.04M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.83M | -66.1% |
| FY2024 | Dec 31, 2024 | $5.40M | -10.6% |
| FY2023 | Dec 31, 2023 | $6.04M | +27.1% |
| FY2022 | Dec 31, 2022 | $4.75M | +134.2% |
| FY2021 | Dec 31, 2021 | $2.03M | -7.8% |
| FY2020 | Dec 31, 2020 | $2.20M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.12M | +159.8% |
| Q2 FY2026 | Jun 30, 2026 | $1.07M | +104.4% |
| Q1 FY2026 | Mar 31, 2026 | $341.47K | -43.0% |
| Q4 FY2025 | Dec 31, 2025 | $281.81K | -65.8% |
| Q3 FY2025 | Sep 30, 2025 | $429.69K | -64.1% |
| Q2 FY2025 | Jun 30, 2025 | $524.21K | -71.3% |
| Q1 FY2025 | Mar 31, 2025 | $598.80K | -61.5% |
| Q4 FY2024 | Dec 31, 2024 | $825.06K | -57.5% |
| Q3 FY2024 | Sep 30, 2024 | $1.20M | -11.2% |
| Q2 FY2024 | Jun 30, 2024 | $1.83M | +5.1% |
| Q1 FY2024 | Mar 31, 2024 | $1.56M | +53.1% |
| Q4 FY2023 | Dec 31, 2023 | $1.94M | +35.6% |
| Q3 FY2023 | Sep 30, 2023 | $1.35M | -15.2% |
| Q2 FY2023 | Jun 30, 2023 | $1.74M | +90.5% |
| Q1 FY2023 | Mar 31, 2023 | $1.02M | +24.0% |
| Q4 FY2022 | Dec 31, 2022 | $1.43M | +100.0% |
| Q3 FY2022 | Sep 30, 2022 | $1.59M | +41.2% |
| Q2 FY2022 | Jun 30, 2022 | $911.69K | +858.9% |
| Q1 FY2022 | Mar 31, 2022 | $818.89K | +791.0% |
| Q4 FY2021 | Dec 31, 2021 | $716.22K | +56.5% |
| Q3 FY2021 | Sep 30, 2021 | $1.13M | +70.8% |
| Q2 FY2021 | Jun 30, 2021 | $95.07K | -76.3% |
| Q1 FY2021 | Mar 31, 2021 | $91.91K | – |
| Q4 FY2020 | Dec 31, 2020 | $457.53K | – |
| Q3 FY2020 | Sep 30, 2020 | $659.98K | – |
| Q2 FY2020 | Jun 30, 2020 | $400.74K | – |
See a number that looks wrong?